Albemarle Corp. stock (US0126531013): Berenberg raises target to $192

Albemarle Corp. shares are in focus on the New York Stock Exchange after Berenberg lifted its target to $192 on 06/02/2026, while the stock traded at $163.93 in recent market data.

Albemarle Corp. stock drew fresh attention on the NYSE after Berenberg Bank raised its price target to $192 from $153 and kept a hold rating in a note dated 06/02/2026, according to MarketBeat and MarketScreener coverage of the update. The same stream of market data put the shares at $163.93, with the latest target implying a wider valuation gap than the prior $153 call, while a separate March 4 note from Truist Securities reiterated a Buy rating and a $210 target on lithium momentum.

For investors following the United States listing, that combination keeps the focus on Albemarle's lithium exposure and on how far analyst expectations remain ahead of the current quote on the NYSE. The stock is also tracked in Germany through secondary market venues, which can matter for local readers comparing the U.S. move with euro-denominated trading hours.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Albemarle Corp.
• Sector/industry: Specialty chemicals, lithium and materials
• Headquarters/country: Charlotte, United States
• Core markets: United States, China, Europe, and other global battery-materials markets
• Key revenue drivers: Lithium compounds, bromine specialties, and catalysts
• Home exchange/listing venue: NYSE (ALB)
• Trading currency: USD

Albemarle Corp.: core business model

Albemarle sells specialty chemicals with a major focus on lithium compounds for batteries, alongside bromine-based products and catalysts that support industrial and energy applications.

Albemarle Corp. in peer comparison

Recent analyst coverage has kept Albemarle in the same conversation as other battery-materials and specialty-chemicals names, with the latest visible update from Berenberg setting a $192 target and a hold rating on 06/02/2026. Truist's March 4 note stood on the more constructive side with a Buy rating and a $210 target, underscoring the range of views around lithium pricing and margin recovery.

Peer context matters because Albemarle's share performance still depends heavily on lithium fundamentals, while competitors in adjacent chemicals and materials categories are assessed against different end markets and pricing cycles. That makes the stock's NYSE pricing a useful reference point for comparing how investors are discounting the current lithium cycle versus broader specialty-chemicals demand.

Conclusion

Berenberg's higher target and Truist's earlier Buy call leave Albemarle framed by competing views on lithium momentum rather than a single dominant narrative. For now, the stock's U.S. listing and home-country analyst coverage remain the key anchors for readers tracking the next move.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.